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against routine spinal MRI for cLBP in primary care, MC may be underdiagnosed. Serum biomarkers for
MC would allow early diagnosis, inform clinical care decisions, and supplement treatment monitoring. We
aimed to discover biomarkers in the blood serum that correlate with MC pathophysiological processes.
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Abstract: Vertebral endplate bone marrow lesions, visualized on magnetic resonance imaging (MRI)
as Modic changes (MC), are associated with chronic low back pain (cLBP). Since guidelines
recommend against routine spinal MRI for cLBP in primary care, MC may be underdiagnosed.
Serum biomarkers for MC would allow early diagnosis, inform clinical care decisions, and supplement
treatment monitoring. We aimed to discover biomarkers in the blood serum that correlate with MC
pathophysiological processes. For this single-site cross-sectional study, we recruited 54 subjects with
38 cLBP patients and 16 volunteers without a history of LBP. All subjects completed an Oswestry
Disability Index (ODI) questionnaire and 10-cm Visual Analog Score (VAS) for LBP (VASback) and leg
pain. Lumbar T1-weighted and fat-saturated T2-weighted MRI were acquired at 3T and used for MC
classification in each endplate. Blood serum was collected on the day of MRI. Biomarkers related to disc
resorption and bone marrow fibrosis were analyzed with enzyme-linked immune-absorbent assays.
The concentration of biomarkers between no MC and any type of MC (AnyMC), MC1, and MC2
were compared. The Area Under the Curve (AUC) of the Receiver Operating Characteristics were
calculated for each biomarker and for bivariable biomarker models. We found that biomarkers
related to type III and type IV collagen degradation and formation tended to correlate with the
presence of MC (p = 0.060–0.088). The bivariable model with the highest AUC was PRO-C3 + C4M
and had a moderate diagnostic value for AnyMC in cLBP patients (AUC = 0.73, specificity = 78.9%,
sensitivity = 73.7%). In conclusion, serum biomarkers related to the formation and degradation of
type III and type IV collagen, which are key molecules in bone marrow fibrosis, correlated with MC
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presence. Bone marrow fibrosis may be an important pathophysiological process in MC that should
be targeted in larger biomarker and treatment studies.
Keywords: Modic change; low back pain; biomarker; connective tissue; basement membrane; bone
marrow; disc degeneration
1. Introduction
Modic changes (MCs) are MRI signal intensity features within vertebrae adjacent to degenerated
intervertebral discs [1–3]. There are three interconvertible types that are defined according to their
appearance on T1-weighted and T2-weighted MR images [2]. In a systematic review, the prevalence
of MC in patients with chronic low back pain (cLBP) was 43% (in contrast to 6% in the non-clinical
population) [4] but varied greatly with geographic location. Generally, prevalence is lower in Asia
(China and India: 10.9–22.4%) [5–7] and Africa (Nigeria: 22.8%) [8]. Prevalence increases with age and
is most frequent at lower lumbar levels, i.e., L4/L5 and L5/S1 [2,9]. Endplate defects predict MC and
suggest biomechanical aspects as important etiological parameters of MC [3,10].
MC have a high specificity for discography-concordant cLBP [11]. In contrast to disc herniation,
where nerve compression causes back and leg pain, MC pain is believed to arise from pathologic
innervation in the endplate and vertebra [11–13]. From a clinical population-based study, including
412 Danes, Kjaer et al. concluded that “MC in combination with disc degeneration is an entity on its
own, which is different from disc degeneration without MC” [14]. LBP patients with MC report a
greater frequency and duration of LBP episodes, seek care more often and have a higher risk for a
poor outcome [4,15–18]. The larger the MC lesions, the lower the chance for resolution, and the higher
the positive predictive value for pain in discography [9,19]. Therefore, early detection of MC may be
important for informing clinical decisions and treatment monitoring [20–22]. However, MC may be
underdiagnosed in primary care because clinical guidelines recommend against routine spine MRI for
“unspecific” cLBP. Serum biomarkers are a fast and inexpensive way to detect pathological conditions.
A robust MC biomarker should reflect the pathophysiological processes (face validity).
MC have been described as inflammatory changes with fibrosis, increased vascular supply, and high
bone turnover [2,10,23,24]. Discs adjacent to MCs degenerate at an increased rate and secrete higher
levels of pro-inflammatory cytokines and aggrecanases [10,24–28]. No biomarkers for MC have yet
been identified. Yet, a small French study reported elevated high-sensitivity C-reactive protein (hsCRP)
in patients with Modic type 1 changes (MC1) [29]. HsCRP is a non-specific marker for inflammation
and hence not a robust biomarker. A recent study on 80 subjects investigated the concentrations of
46 serum cytokines between MC patients and healthy volunteers [30]. Interestingly, 16 cytokines
related to inflammation, bone turnover, angiogenesis, and vascular injury were downregulated in MC.
In a case-control study, with 13 MC1 patients and 21 control cLBP patients without MC, Boisson et al.
found no difference in serum markers of inflammation (interleukin (IL)-1β, IL-6, IL-8, tumor necrosis
factor alpha (TNF-α)) [31]. This stands in contrast to the current ideas about MC pathophysiology.
Therefore, blood serum cytokines may have little face validity for MC. Blood biomarkers for oxidative
stress (total thiols, advanced oxidation protein products, and carbonyl groups) in MC1 patients are
inconclusive [31,32] and degradation markers for type II collagen (Coll2-1, Coll2-1NO2), important
disc collagen, were not elevated in MC1 patients [31]. Taken together, these studies do not yet validate
the concept of ‘active discopathy’, defined as an accelerated disc degeneration with low grade local
and systemic inflammation [33]. However, no study has yet investigated biomarkers related to bone
marrow fibrosis, which is a histological hallmark of MC.
We aimed to detect biomarkers reflecting connective tissue and basement membrane turnover for
MC that have high face validity. These biomarkers may relate to the rapid resorption of the adjacent disc
and the fibrotic changes of the bone marrow. The disc matrix consists mainly of type I and II collagen,
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as well as aggrecan. Type III collagen is present only in traces in the pericellular environment of disc
cells and type IV collagen is absent [34,35]. Therefore, resorption of the disc generates neo-epitopes of
type I and II collagen and aggrecan. In myelofibrosis (a fibrotic condition of the bone marrow different
from MC), type I and III collagen are the major deposited matrix constituents [36]. Neovascularization
of fibrotic bone marrow increases the spatial abundance of type IV collagen because type IV collagen is
the main constituent of the basement membrane of vascular sinusoids [37,38]. Serum procollagen type
III and IV are known to be increased in myelofibrosis [39]. Therefore, biomarkers for type III and IV
collagen, but not type I and II collagen and aggrecan, may relate to bone marrow fibrosis. In this current
study, we quantified the association of nine matrix biomarkers related to disc resorption and bone
marrow fibrosis (neo-epitopes of type I to IV pro-collagen (PRO-C1, PRO-C2, PRO-C3, PRO-C4), type I
to IV collagen degradation neo-eiptopes (C1M, C2M, C3M, C4M, aggrecan degradation neo-epitope
(huARGS)) to lumbar MC. Since a previous study reported no increase in type II collagen degradation
markers [31], we hypothesized that biomarkers related to bone marrow fibrosis are increased in MC.
We observed that serum biomarkers related to the formation and degradation of type III (PRO-C3,
C3M) and type IV collagen (PRO-C4, C4M), correlated with MC presence. This underscores that bone
marrow fibrosis is an important pathophysiological process in MC, and suggests that it should be a
focus in larger biomarker and treatment studies.
2. Results
2.1. Study Subjects
There were no significant differences in sex, age, and body mass index (BMI) between cLBP
patients and control subjects or between subjects with any type of MC (AnyMC) and without MC
(Table 1). Oswestry Disability Index (ODI), visual analogue score (VAS) for back pain (VASback),
and VAS for leg pain (VASleg) were significantly higher in the patient group than in the control group
but not different between LBP patients with AnyMC and without MC. The occurrence of MC was
higher in the patient group (50.0% vs. 12.5%, p = 0.01), mainly because of increased presence of MC1 in
the patient group (26.3% vs. 0%, p = 0.03. MC2 (28.9% vs. 12.5%, p = 0.30) and MC3 (5.3% vs. 0%,
p = 1.00) were also more common in the patient group but not significantly. Six patients had MC1 and
MC2. Inter-rater reliability of MC classification was κ = 0.838.
Table 1. Demographic information of low back pain (LBP) patients and control subjects.
Characteristics
LBP Patients (n = 38) Control Subjects (n = 16) LBP vs. Control
AnyMC No MC p-Value AnyMC No MC p-Value p-Value
MC prevalence
AnyMC 19 (50.0) 19 (50.0) 2 (12.5) 14 (87.5) 0.01 *
MC1 10 (26.3) 28 (73.7) - 0 (0) 16 (100) - 0.03 *
MC2 11 (28.9) 27 (71.1) - 2 (12.5) 14 (87.5) - 0.30
MC3 2 (5.3) 36 (94.7) - 0 (0) 16 (100) - 1.00
Demographics and clinical measures
Male 8 (44.4) 12 (60.0) 0.33 1 (50.0) 7 (50.0) 1 0.21
Age 47.7 ± 12.1 47.9 ± 11.7 0.97 57.0 ± 9.9 42.3 ± 11.3 0.24 0.36
BMI 25.9 ± 6.0 25.8 ± 4.0 0.98 27.5 ± 2.6 23.1 ± 3.6 0.18 0.48
VASback 6.6 ± 1.8 6.5 ± 1.7 0.85 0 ± 0 0 ± 0 - <0.001 ***
VASleg 3.6 ± 3.2 4.5 ± 3 0.41 0 ± 0 0 ± 0 - <0.001 ***
ODI * 34 ± 14.2 31.9 ± 15.6 0.67 0 ± 0 0 ± 0 - <0.001 ***
For continuous numerical variables (Age, BMI, ODI), mean values ± standard deviations are indicated.
Group differences were tested with t-tests. For count data (Male), the count is indicated and the percentage
is in the parentheses. Group differences were tested with Fisher exact tests. BMI: body mass index; VAS: visual
analog score; MC: Modic change; AnyMC: any type of MC; MC1: MC type 1; MC2: MC type 2; MC3: MC type 3.
Significant correlations are marked with asterisks: * p < 0.05, *** p < 0.001.
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2.2. Serum Biomarker with Modic Changes
Nine serum biomarkers related to disc and bone marrow connective tissue and basement
membrane remodeling were measured (Table 2). In subjects with AnyMC, C4M was increased (+6.1%;
p = 0.048; 25.6 ng/mL) and C3M (+5.4%; p = 0.091; 12.2 ng/mL) and PRO-C4 (+21.6%; p = 0.091;
250.6 ng/mL) tended to be increased compared to control subjects (24.1 ng/mL, 11.6 ng/mL, 206.0 ng/mL,
respectively) (Table A1, Figure 1a). Other biomarkers showed no differences. In subjects with lumbar
MC1, only PRO-C3 tended to be elevated (+9.2%; p = 0.092; 8.93 ng/mL vs. 8.18 ng/mL). In subjects with
lumbar MC2, PRO-C4 was significantly up-regulated (+23.7%; p = 0.038; 254.9 ng/mL vs. 206.0 ng/mL),
while C3M (+5.9%; p = 0.059; 12.3 ng/mL vs. 11.6 ng/mL) and C4M (+4.9%; p = 0.062; 25.3 ng/mL vs.
24.1 ng/mL) showed trends for elevation.
Table 2. Serum biomarkers.
Biomarker Specification Inter-Assay CV% No. of Undetectable Samples
PRO-C1
Internal epitope in the N-terminal
pro-peptide of type I collagen
<8.7% 2
PRO-C2












Neo-epitope of MMP-2,9,13 mediated




degradation of type II collagen
<5.2% 0
C3M
Neo-epitope of MMP-9 mediated
degradation of type III collagen
<4.5% 0
C4M
Neo-epitope of MMP-2,9,12 mediated




N-terminal epitope of aggrecanase
mediated degradation of aggrecan
<7.7% 0












Figure 1. Biomarkers for turnover of type III and type IV collagen in (a) all subjects and (b) low back
pain patients only. Horizontal lines indicate median value. P-values for comparison of Modic change
(MC) groups (Any MC, MC1, MC2) versus no MC are given. AnyMC = any type of Modic change;
MC1 =Modic type 1 change; MC2 =Modic type 2 change.
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When the analysis was restricted to cLBP patients only, which reflects the clinical situation, C3M
(+16.7%; p = 0.088; 12.2 ng/mL vs. 10.5 ng/mL), PRO-C3 (+15.0%; p = 0.071, 8.49 ng/mL vs. 7.38 ng/mL),
C4M (+8.7%; p = 0.060; 25.6 ng/mL vs. 23.6 ng/mL), and PRO-C4 (+40.2%; p = 0.085; 250.6 ng/mL vs.
178.7 ng/mL) tended to be up-regulated in patients with AnyMC (Table A2, Figure 1b). In addition,
PRO-C3 was significantly upregulated in patients with MC1 (+21.0%; p = 0.045; 8.93 ng/mL) and with
MC2 (+17.3%; p = 0.033; 8.66 ng/mL) compared to patients without MC (7.38 ng/mL). The biomarker
concentrations did not correlate with the total number of MCs within subjects (data not shown).
Effect sizes (Cohen’s d) were 0.51, 0.53, 0.52, and 0.61. Post-hoc power analysis indicated low
power: 0.35, 0.37, 0.36, and 0.47 for PRO-C3, PRO-C4, C3M, and C4M, respectively.
2.3. Correlation Analysis
Correlation between biomarkers: C3M correlated positively with PRO-C4 (r = 0.71, p < 0.001) and
C4M (r = 0.89, p < 0.001) (Table A3). C4M correlated also positively with PRO-C4 (r = 0.74, p < 0.001).
C2M correlated negatively with huARGS (r = −0.48, p < 0.001). All other correlations between
biomarkers were not significant.
Correlation of biomarkers with patient data: HuARGS correlated weakly with age (r = −0.38,
p = 0.03). PRO-C4 correlated weakly with Oswestry Disability Index (ODI) in cLBP patients (r = 0.37,
p = 0.02), but not anymore after adjustment for multiple testing (p = 0.18). All other correlations were
not significant. Of the four biomarkers (PRO-C3, PRO-C4, C3M, C4M) that correlated with MC, PRO-C4,
C3M, and C4M correlated with each other. PRO-C3 did not correlate with any other biomarker.
2.4. Receiver Operating Characteristics Analysis
Receiver operating characteristics were calculated for PRO-C3, PRO-C4, C3M, and C4M. These were
the biomarkers that correlated either with AnyMC, MC1, or MC2, using all subjects or patients only.
PRO-C3 had the largest AUC for MC1 and MC2, for all the subjects (MC1: 0.66, 95% CI: 0.48–0.84;
MC2: 0.65, 95% CI: 0.47–0.83) and for patients only (MC1: 0.70, 95% CI: 0.50–0.89; MC2: 0.72, 95% CI:
0.53–0.90) (Table 3). When data were not stratified for MC type, PRO-C4 had the largest AUC when all
subjects were considered (0.62, 95% CI: 0.59–0.64), and C3M had the largest AUC when patients only
were considered (0.64, 95% CI: 0.46–0.82).
We next calculated ROC for AnyMC, MC1, and MC2 for combinations of PRO-C3 with PRO-C4,
C3M, and C4M (Table 4). The model PRO-C3 + C4M had the highest AUC for AnyMC (all subjects
and patient only) and MC1 (patient only). The model PRO-C3 + PRO-C4 had the highest AUC for
MC2 (all subjects and patients only). The model PRO-C3 + C3M had the highest AUC for MC1 when
considering all subjects.
Considering the clinical situation, where a test for the presence of MC in cLBP patients is desirable,
the bivariable model PRO-C3 + C4M had the highest AUC 0.73 (95% CI: 0.56–0.90). Specificity was
78.9% (95% CI: 57.9–94.9) and sensitivity was 73.7% (95% CI: 47.4–94.7).
Table 3. Area Under the Curve (AUC) of Receiver Operating Characteristics (ROC).
Biomarker
All Subjects Patients Only
AnyMC MC1 MC2 AnyMC MC1 MC2
PRO-C3 0.58 (0.41, 0.74) 0.66 (0.48, 0.84) 0.65 (0.47, 0.83) 0.63 (0.44, 0.81) 0.70 (0.50, 0.89) 0.72 (0.53, 0.90)
PRO-C4 0.62 (0.46, 0.78) 0.59 (0.37, 0.82) 0.64 (0.45, 0.82) 0.63 (0.45, 0.82) 0.61 (0.38, 0.84) 0.63 (0.42, 0.83)
C3M 0.61 (0.45, 0.77) 0.60 (0.43, 0.78) 0.62 (0.43, 0.81) 0.64 (0.46, 0.82) 0.63 (0.44, 0.81) 0.63 (0.43, 0.84)
C4M 0.61 (0.45, 0.76) 0.59 (0.42, 0.77) 0.58 (0.40, 0.76) 0.62 (0.43, 0.80) 0.60 (0.41, 0.79) 0.57 (0.37, 0.77)
Only biomarkers with significant correlations or strong trends for correlation with Modic changes were evaluated.
The mean value for Area under the curve (AUC) is indicated. 95% confidence interval in brackets. AnyMC = any
type of Modic change; MC1 =Modic type 1 change; MC2 =Modic type 2 change.
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Table 4. Receiver Operating Characteristics (ROC) of best bivariable biomarker models.
MC Type Subjects Model AUC Specificity (%) Sensitivity (%)
AnyMC
all PRO-C3 + C4M 0.67 (0.52, 0.83) 90.9 (51.5, 100) 52.4 (28.6, 85.7)
patients PRO-C3 + C4M 0.73 (0.56, 0.90) 78.9 (57.9, 94.9) 73.7 (47.4, 94.7)
MC1
all PRO-C3 + C3M 0.69 (0.52, 0.86) 61.4 (43.2, 81.9) 90.0 (60.0, 100)
patients PRO-C3 + C4M 0.70 (0.51, 0.89) 67.9 (46.4, 85.7) 90.0 (60.0, 100)
MC2
all PRO-C3 + PRO-C4 0.72 (0.55, 0.88) 75.6 (29.3, 100) 76.9 (38.5, 100)
patients PRO-C3 + PRO-C4 0.75 (0.60, 0.91) 59.3 (37.0, 100) 100 (54.5, 100)
Mean value indicated for Area under the curve (AUC), specificity, and sensitivity with a 95% confidence interval in
brackets. Age, gender, and BMI were not included in the models because they did not significantly correlate with
MC. AnyMC = any type of Modic change; MC1 =Modic type 1 change; MC2 =Modic type 2 change.
3. Discussion
We measured serum biomarkers of extracellular matrix turnover related to disc and bone marrow
in subjects with and without MC and tested these biomarkers’ ability to predict MC. We found
that biomarkers related to type III and IV collagen degradation (C3M and C4M, respectively) and
formation (PRO-C3 and PRO-C4, respectively) correlated with the presence of MC in patients with
cLBP (p = 0.060–0.088). PRO-C3 in combination with C4M had a moderate diagnostic value for MC in
cLBP patients (AUC = 0.73, specificity = 78.9%, sensitivity = 73.7%).
These results agree with the pathomolecular mechanism of MC, in particular MC1, where bone
marrow fibrosis has been described [2,10]. Type III and IV collagen are key bone marrow matrix
constituents and known to be increased in bone marrow fibrosis [36]. From biomarker studies of other
fibrotic diseases, including myelofibrosis, it is likely that an increase of PRO-C3 correlates with an
increased type III collagen deposition. An increased C4M (and in some analysis PRO-C4) indicates
a remodeling of tissue vascularization as type IV collagen is an important basement membrane
constituent. This is in agreement with previous reports of decreased pro-angiogenic serum cytokines
in MC patients, i.e., vascular endothelial growth factor (VEGF)-C, VEGF-D, tyrosine-protein kinase
receptor 2 (Tie-2), VEGF receptor 1 (Flt-1), intercellular adhesion molecule 1 (ICAM-1), vascular cell
adhesion molecule 1 (VCAM-1) [30]. Biomarkers related to disc degradation were not increased (C1M,
C2M, huARGS), indicating that disc resorption is not a specific mechanistic target for MC, as previously
reported [31].
Bone marrow fibrosis and accelerated disc degeneration are hallmarks of MC [2,3,10,11,33].
Extracellular matrix biomarkers related to these processes could be valuable in detecting MC at an
early stage of the typically long treatment history of cLBP patients. In this study, we found that
circulating biomarkers related to bone marrow fibrosis (PRO-C3, C3M, PRO-C4, C4M) but not to
disc degeneration (C1M, C2M, huARGS) were increased in cLBP patients with MC. Our statistical
models with the highest diagnostic accuracy for MC were combinations of PRO-C3 with PRO-C4,
C3M or C4M, depending on the type of MC. Correlation analysis between the different biomarkers
showed that PRO-C4, C3M, and C4M correlate significantly with each other, and hence, combining
C3M, and C4M did not enhance diagnostic value. PRO-C3 did not correlate with PRO-C4, C3M, and
C4M, and, therefore, the combination of PRO-C3 with any of the other three biomarkers increases the
diagnostic value. The best model in this study for AnyMC in cLBP patients was PROC3 + C4M and
reached a moderate diagnostic value with an AUC = 0.73. While this is not satisfactory for clinical
usage, the correlation of fibrosis-related serum biomarkers with MC indicates that bone marrow
fibrosis is an active process in MC. Marrow fibrosis in MC has been mainly associated with MC1 but
not MC2 [2,10]. Interestingly, we found significantly increased serum concentrations of PRO-C4 and
PRO-C3 in subjects with MC2. The model PRO-C3 + PRO-C4 had a classification accuracy for MC2
with an AUC = 0.75 and a sensitivity of 100%. This suggests that bone marrow fibrosis is also a relevant
pathomechanism in MC2. Histopathological studies of MC2 bone marrow will have to corroborate the
fibrotic mechanisms in MC2.
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The biomarkers PRO-C3, PRO-C4, C3M, and C4M that correlate with MC have been identified as
markers for other fibrotic conditions. In myelofibrosis, a myeloproliferative and fibrotic disease of
the bone marrow, serum PRO-C3 and PRO-C4 have already been described as potential biomarkers
that correlate with increased type III and IV collagen in the bone marrow [36–40]. PRO-C4 has been
identified as a serum marker to predict the progression of systemic sclerosis [41]. PRO-C3 has been
suggested as a biomarker for several pathologies related to tissue fibrosis such as lung injury, viral and
non-viral hepatitis, systemic sclerosis, vascular remodeling, and kidney diseases [42]. The epitope
recognized by the PRO-C3 assay is generated by cleaving intact procollagen type III. The cleaved
N-terminal fragment is liberated into the systemic level and measured in the blood serum. Hence, PRO-C3
correlates stoichiometrically with type III collagen formation.
The type IV collagen neoepitope C4M is increased in idiopathic pulmonary fibrosis, chronic
obstructive pulmonary disease, and liver fibrosis [43]. The epitope recognized by the C4M assay is
exposed when matrix metalloproteinase-2 and -9 (MMP-2, MMP-9) cleave intact type IV collagen,
a major component of the basement membranes, including basement membranes from vascular
sinusoids in the bone marrow. The activity of the gelatinases MMP-2 and -9 is locally increased in
fibrotic tissue and disrupts the basement membrane, and allows the infiltration of fibroblasts and
macrophage. Similarly, the type III collagen neoepitope C3M is exposed when MMP-9 cleaves intact
type III collagen. C3M is a biomarker for liver fibrosis [44]. The specificity of these biomarkers for
local fibrotic pathomechanisms grants them a high test and content validity for fibrotic disorders.
Our data suggest that turnover of type III and IV collagen is increased in patients with MC and that
increased serum concentrations could relate to MC because these patients were not known to have
other fibrotic disorders.
Serum cytokines related to inflammation, bone turnover, angiogenesis, and vascular injury have
recently been investigated as MC biomarkers [21,30,31]. However, no correlations were found with
local pathophysiological processes. Therefore, these cytokines only have limited test validity. Cytokines
have an average half-life in the range of minutes to hours [45], which allows the human body to react
with a fast and dynamic cytokine response. Consequently, serum cytokine levels are very dynamic.
In contrast, collagens are by the nature of their function thermodynamically very stable. For example,
collagens of human intervertebral discs have an average half-life of 95–215 years [46]. Although
collagen fragments may have a reduced half-life compared to intact collagen, they are more stable
biomarkers than cytokines and are less affected by the diurnal cycle, food intake, and other acute
events. In MC, inflammation is indicated by the edema seen on fat-saturated T2-weighted and on
T1-weighted MR images. Yet, there is no direct evidence of inflammation in MC bone marrow [10].
Discs adjacent to MC were reported to secrete higher levels of inflammatory cytokines [10,24,26,27].
However, degenerated discs contain very few cells (<1 Mio) [47], and a small increase of inflammatory
cytokine secretion is not detected on a systemic level, with no positive correlations with presence and
size of MC [21].
The clinical relevance of MC is controversial [48,49]. Variability in the identification, classification,
and reporting of MC contribute to discrepancies between study findings [50]. Besides known
methodological factors related to imaging, time-varying changes in MC pathophysiology may contribute
to the inconsistent findings. For example, fibrosis and bone resorption/high bone turnover are both
hallmarks of MC [2,10,23]. These processes may occur in distinct phases. Therefore, serum biomarkers
for bone marrow fibrosis, i.e., for PRO-C3, PRO-C4, and C4M, may not only help to detect MC but
also help to stratify patients into a “fibrotic phase” and an “inflammatory bone resorption phase”.
This could potentially inform treatment decisions and monitoring.
This study had several limitations. It was a single-site study with 54 participants with only
10 cLBP patients with MC1 and 11 cLBP patients with MC2. Variation in all biomarker concentration
was high (Cohen’s d < 0.61 for AnyMC vs. no MC). Therefore, posthoc power analysis resulted in low
power (power < 0.47). Despite the low power, differences in type III and IV collagen turnover suggest
bone marrow fibrosis as a relevant MC pathomechanism. However, these findings need to be validated
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in independent cohorts. Given the limited number, it is important to note that there was no difference
in gender, age, and BMI between patients and the control group and between subjects with and
without MC. Nevertheless, results should be interpreted carefully and not over-generalized. The small
participant number also limited the construction of more powerful statistical models. For example,
including available patient data (sex, age, BMI) in biomarker models may improve the diagnostic
accuracy. In order to avoid overfitting, we limited construct complexity to two biomarkers. Patient
data were not included because they did not correlate with the presence of lumbar MC in our sample.
Despite the limited data, fibrosis-related biomarkers were consistently upregulated and allowed for
careful interpretation.
The causal relationship of serum type III and IV collagen with the pathological mechanism of
MC remains unknown. Low local inflammation, as well as altered biomechanical loads, may both be
factors contributing to bone marrow fibrosis. Clarification of these relationships requires cross-sectional
histological studies as well as longitudinal studies that investigate the correlation of these biomarkers
with MC progression and clinical parameters.
Bone marrow lesions (BML) in osteoarthritic joints share many characteristics with MC1, including
pain association, natural history, local inflammation, and degradation of the adjacent cartilage [47].
Therefore, assessing biomarkers for type III and IV collagen in patients with osteoarthritic BML will
gauge their specificity for MC and indicate pathomechanistic similarities between MC and BML in
osteoarthritic joints.
MC size, type, and number may also affect serum biomarker concentration. In this current study,
a correlation analysis of the number of MC lesions with serum biomarker concentrations revealed
no significance.
Six patients had both MC1 and MC2, and some MC were of mixed type. Subgroup analysis for
MC1 and MC2 showed similar biomarker trends. Nevertheless, MC1 and MC2 present different stages
of the pathomechanism and have different histological features [2,10,11]. Therefore, larger, longitudinal
studies are required in order to define accurate biomarkers for MC1 and MC2.
4. Materials and Methods
The study was conducted in accordance with the Declaration of Helsinki and approved by the site’s
Institutional Research Board (#13-12224; approved 21 August 2014) and the local Ethics Commission
(#2019-00845; approved 16 May 2019). Informed consent was obtained from each subject.
4.1. Study Subjects
The prospective cross-sectional study included 16 volunteers (no LBP, VASback ≤ 1), and 38 cLBP
patients. Chronic LBP was defined as having LBP for more than three consecutive months and VASback
≥ 4 or ODI ≥ 30%. All subjects were recruited from outpatient clinics and from electronic medical
records, and were enrolled between January 2016 and July 2018. Exclusion criteria were applied
based on past medical history and MRI and were pregnancy, diabetes, positive smoking status, cancer,
spondylolisthesis, scoliosis, prior lumbar surgery, disc herniation, compression fracture, and active use
of osteoporosis medication. Patients and volunteers were age and sex-matched. All subjects completed
a 10-item ODI questionnaire and indicated the intensity of back and leg pain on a 10-cm visual analog
scale (VASback and VASleg, respectively).
4.2. Blood Serum Analysis
Peripheral blood was collected into serum-separating tubes (BD Bioscience). After 30 min at
room temperature, the tubes were spun for 10 min at 1300× g at room temperature. The serum
was frozen at −80 ◦C until analysis. Hemolysis was scored on a scale 0–3. All samples passed
hemolysis test. The serum biomarkers were analyzed using enzyme-linked immunosorbent assays
(ELISA). Each ELISA plate contained five controls and samples were run in duplicates in a blinded
way. A coefficient of variance on duplicates of 15% was allowed. Samples with CV > 15% were rerun.
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Inter-assay variations from the five control samples are given in Table 2. No detectable amounts were
set to the sensitivity level of the assay.
4.3. Magnetic Resonance Imaging (MRI)
The MRI of the lumbar spine was done at the time of blood serum collection in patients and
volunteers. MRI was performed on a Discovery MR 750 3-T scanner using an eight-channel phased-array
spine coil (GE Healthcare). Clinical fast spin-echo images with T1 and T2 weighting were acquired
in the sagittal orientation with a field-of-view of 26 cm and slice thickness of 4 mm. Fat-saturated
T2-weighted images had an echo time (TE) = 60 ms, repetition time (TR) = 4877 ms, echo train length
(ETL) = 24, readout-bandwidth (rBW) = ±50 kHz, and an in-plane resolution of 0.6 mm. T1-weighted
images had TE = 15 ms, TR = 511 ms, ETL = 4, BW = ±50 kHz, and an in-plane resolution of 0.5 mm.
Lumbar MC were graded by C.O. and Z.M. Both are board certified in pain medicine and have
20 years (C.O.) and eight years (Z.M.) of experience in reading and interpreting spine MRIs for
clinical and research purposes. T1-and fat-saturated T2-weighted images were used to classify MC
types according to the standard MC definition, which is MC1 = hypointense/hyperintense on T1/T2,
MC2 = hyperintense/iso-to-hypointense on T1/T2, and MC3 = hypointense/hypointense on T1/T2 [50].
The cranial and caudal part of each lumbar vertebra was rated separately. To gauge inter-rater reliability
of MC grading, both raters scored a subset of 45 vertebrae.
4.4. Statistical Analysis
Statistical analysis was done using R v. 3.6.2. For all tests, the significance level was set to α = 0.05.
For power calculations, the power.t.test function of the package pwr in R was used. This was an
exploratory study using convenience samples from patients that were recruited for a radiological study.
In total, 42 cLBP patients and 18 healthy volunteers were recruited. One patient had to be excluded
due to an infectious disease, and five blood samples had a nonacceptable level of hemolysis (>1).
With the remaining n = 19 per group (AnyMC, no MC) in the cLBP population, an effect size of Cohen’s
d = 0.91 was required to reach a power of 0.8. No preliminary data of the measured biomarkers were
available for cLBP patients to gauge the effect size. A previous study in cLBP patients measuring
hsCRP revealed a Cohen’s d of 1.46–1.72 [29]. A similar effect size would require a group size of n = 6–8.
Post-hoc power was calculated for AnyMC for PRO-C3, PRO-C4, C3M, and C4M. Kappa statistic was
used to assess inter-rater reliability of MC classification. For demographic information, differences
between the two groups were tested with two-sided t-tests or Fisher exact tests for numeric and
dichotomous data, respectively. The concentration of biomarkers were compared between two groups
with t-tests or Wilcoxon rank-sum test if the Anderson–Darling test indicated non-normal distributed
data. The correlations between biomarkers and patient information (age, sex, BMI) and between
different biomarkers were tested with Pearson’s product-moment and corrected for multiple testing
with the Benjamin–Hochberg correction (false discovery rate). Receiver operating characteristics (ROC),
including the Area Under the Curve (AUC), sensitivity, specificity, and accuracy were computed using
the pROC package in R (v. 1.16.1) for each biomarker that correlated with the presence of any type of
lumbar MC (AnyMC), MC1, or MC2. Logistic regression models were calculated for combinations of
two biomarkers. No sub-group analysis for MC3 was made because only two patients had MC3.
5. Conclusions
Serum biomarkers related to type III and IV collagen formation and degradation correlated with
the presence of lumbar MCs in patients with cLBP. A multivariable statistical model, including PRO-C3
and C4M reached moderate diagnostic value to detect MC (AUC = 0.73). Together, these data indicate
that bone marrow fibrosis in MC may be an important pathophysiological process that could be
targeted in future biomarker studies that include more patients and quantitative MC evaluation.
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Abbreviations
cLBP Chronic low back pain
MC Modic change
MC1 Modic type 1 change
MC2 Modic type 2 change
MC3 Modic type 3 change
AnyMC Any type of Modic change
VASback Visual Analog Score for back pain
VASleg Visual Analog Score for leg pain
ELISA Enzyme-linked immunosorbent assay
MRI Magnetic resonance imaging
PRO-C1 Internal epitope in the N-terminal pro-peptide of type I collagen
PRO-C2 Released N-terminal pro-peptide of type II collagen
PRO-C3 Released N-terminal pro-peptide of type III collagen
PRO-C4 Internal epitope in the 7S domain of type IV collagen
C1M Neo-epitope of MMP-2,9,13 mediated degradation of type I collagen
C2M Neo-epitope of MMP-mediated degradation of type II collagen
C3M Neo-epitope of MMP-9 mediated degradation of type III collagen
C4M Neo-epitope of MMP-2,9,12 mediated degradation of type IV collagen alpha 1 chain
huARGS N-terminal epitope of aggrecanase mediated degradation of aggrecan
ODI Oswestry disability index
ROC Receiver operating characteristics
AUC Area under the curve
hsCRP High-sensitivity C-reactive protein
CV Coefficient of variance
TE Echo time
TR Repetition time
ETL Echo train length
rBW Readout-bandwidth
MMP Matrix metalloproteinase
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Appendix A
Table A1. Serum biomarker concentrations of all study subjects.
Biomarker
No MC Any MC MC1 MC2
Median [IQR] Median [IQR] p-Value Median [IQR] p-Value Median [IQR] p-Value
PRO-C1 78.6 (47.76; 101.99) 56.93 (41.14; 98.31) 0.287 56.93 (44.22; 99.78) 0.663 56.8 (41.27; 95.44) 0.560
PRO-C2 29.06 (25.91; 34.41) 27.87 (26.27; 30.16) 0.303 29.27 (27.82; 30.16) 0.565 28.74 (26.36; 30.29) 0.356
PRO-C3 8.18 (6.67; 8.76) 8.49 (8.01; 10.15) 0.336 8.93 (8.31; 9.74) 0.092 8.66 (8.11; 10.89) 0.102
PRO-C4 206.0 (153.6; 244.8) 250.6 (198.5; 334.0) 0.091 253.9 (171.5; 318.2) 0.289 254.9 (212.1; 326.0) 0.038 *
C1M 20.4 (15.63; 26.33) 22.15 (17.08; 26.63) 0.695 22.65 (15.23; 26.4) 0.704 22.1 (18.3; 26.1) 0.681
C2M 0.28 (0.23; 0.34) 0.28 (0.22; 0.41) 0.936 0.29 (0.27; 0.39) 0.564 0.26 (0.21; 0.42) 0.247
C3M 11.57 (9.82; 13.74) 12.2 (11.09; 14.98) 0.091 12.2 (11.24; 14.21) 0.218 12.25 (11.33; 15.29) 0.059
C4M 24.14 (17.58; 28.39) 25.62 (22.4; 34.77) 0.048 * 26.23 (22.73; 28.02) 0.169 25.33 (22.55; 33.56) 0.062
huARGS 458.3 (395.15; 503.95) 430.2 (348.95; 659.65) 0.831 411.1 (358.85; 550.4) 0.961 424.4 (317.2; 667) 0.973
Median values with interquartile ranges (IQR) in parentheses are indicated in ng/mL. Differences between subjects with no Modic change (MC) and with any type of MC (AnyMC),
between no MC and Modic type 1 change (MC1), and no MC and Modic type 2 change (MC2), were compared. Significant correlations are marked with asterisks: * p < 0.05.
Table A2. Serum biomarker concentrations of patients only.
Biomarker
No MC AnyMC MC1 MC2
Median [IQR) Median [IQR) p-Value Median [IQR) p-Value Median [IQR) p-Value
PRO-C1 72.23 (34.89; 91.91) 54.94 (40.89; 92.5) 0.646 56.93 (44.22; 99.78) 0.961 53.08 (41.02; 89.56) 0.549
PRO-C2 29.4 (25.79; 33.98) 27.85 (25.96; 29.57) 0.292 29.27 (27.82; 30.16) 0.634 28.31 (25.68; 29.35) 0.360
PRO-C3 7.38 (6.5; 8.52) 8.49 (8.06; 9.74) 0.071 8.93 (8.31; 9.74) 0.045 * 8.66 (8.21; 10.92) 0.033 *
PRO-C4 178.7 (142.0; 235.8) 250.6 (171.4; 318.2) 0.085 253.9 (171.5; 318.2) 0.184 254.9 (184.9; 305.0) 0.091
C1M 17.5 (15.2; 22.55) 22.15 (14.63; 26.4) 0.362 22.65 (15.23; 26.4) 0.435 22.1 (15.85; 24.5) 0.590
C2M 0.27 (0.24; 0.32) 0.28 (0.23; 0.39) 0.579 0.29 (0.27; 0.39) 0.611 0.26 (0.21; 0.36) 0.707
C3M 10.45 (9.64; 13.79) 12.2 (11.24; 14.76) 0.088 12.25 (11.34; 14.84) 0.159 12.25 (11.34; 14.84) 0.129
C4M 23.58 (17.53; 28.65) 25.62 (22.58; 32.19) 0.060 26.23 (22.73; 28.02) 0.167 25.33 (22.6; 30.06) 0.159
huARGS 465.8 (395.15; 501.3) 449.8 (358.85; 664.55) 0.989 411.1 (358.85; 550.4) 0.559 436 (323.4; 673) 0.919
Median values with interquartile ranges (IQR) in parentheses are indicated in ng/mL. Differences between subjects with no Modic change (MC) and with any type of MC (AnyMC),
between no MC and Modic type 1 change (MC1), and no MC and Modic type 2 change (MC2), were compared. Significant correlations are marked with asterisks: * p < 0.05.
Int. J. Mol. Sci. 2020, 21, 3791 12 of 15
Table A3. Pearson correlation coefficients between different serum biomarkers.
Biomarker PRO-C1 PRO-C2 PRO-C3 PRO-C4 C1M C2M C3M C4M
PRO-C2 −0.17
PRO-C3 0.06 −0.10
PRO-C4 0.06 −0.12 0.05
C1M −0.11 0.01 −0.02 0.01
C2M −0.13 −0.06 0.21 0.13 0.10
C3M −0.22 −0.05 0.10 0.71 *** 0.21 0.28
C4M −0.27 0.10 0.04 0.74 *** 0.19 0.24 0.89 ***
huARGS 0.02 0.00 −0.11 −0.03 −0.16 −0.48 *** −0.16 −0.07
Significant correlations after correction for multiple testing are marked with asterisks: *** p < 0.001.
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